Oragenics Inc. (NYSE American: OGEN) and Sigyn Therapeutics Inc. (OTCQB: SIGY) announced the signing of a letter of intent (LOI) under which Oragenics expects to obtain an exclusive license to develop and commercialize Sigyn’s CardioDialysis™ blood purification technology. The technology is intended for use in traumatic brain injury (TBI) and chronic neurodegenerative diseases, complementing Oragenics’ Phase IIa intranasal neurosteroid candidate ONP-002. This proposed dual-modality approach targets inflammation on both sides of the blood-brain barrier.
According to the press release, the LOI outlines terms for Oragenics to license CardioDialysis, which is designed to remove inflammatory mediators from the blood. This could address the systemic inflammation that often accompanies neurological conditions. Oragenics’ ONP-002 is a potential first-in-class treatment for concussion and mild traumatic brain injury, delivered via proprietary intranasal technology to bypass the blood-brain barrier.
The combination of intranasal ONP-002 and CardioDialysis blood purification could offer a comprehensive strategy: ONP-002 targets inflammation within the brain, while CardioDialysis reduces systemic inflammatory factors. This approach may enhance therapeutic outcomes for patients with TBI and chronic neurodegenerative diseases such as Parkinson’s and Alzheimer’s.
Oragenics is advancing its clinical program for ONP-002, with plans to commence clinical trials in Australia and subsequent U.S. Phase 2b trials. The company’s intranasal delivery platform has potential applications across multiple neurological conditions, including PTSD and anxiety disorders. For more information about Oragenics, visit oragenics.com.
The signing of this LOI marks a strategic expansion for Oragenics, leveraging Sigyn’s blood purification technology to address the inflammatory component of neurological diseases. The full press release is available at https://ibn.fm/VD4RO. For the latest news and updates relating to Oragenics, visit the company’s newsroom at https://ibn.fm/OGEN.
InvestorWire, a specialized communications platform, distributed the press release. It is part of the Dynamic Brand Portfolio @IBN, which offers wire services, editorial syndication, and social media distribution. For more information about InvestorWire, visit https://www.InvestorWire.com. Please see full terms of use and disclaimers on the InvestorWire website.
